Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2022
Price :
$35
*
At a glance
- Drugs Padsevonil (Primary)
- Indications Partial epilepsies; Seizures; Tonic-clonic epilepsy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms DUET
- Sponsors UCB Biopharma; UCB Japan
- 24 Sep 2021 Status changed from completed to discontinued.
- 25 Nov 2020 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 14 Nov 2020 This trial has been completed in Croatia according to European Clinical Trials Database record.